Skip to main content
Top
Published in: Inflammation 1/2024

Open Access 29-08-2023 | RESEARCH

Effects of Inhibition of IKK Kinase Phosphorylation On the Cellular Defence System and HSP90 Activity

Authors: Miriam Giacomarra, Martina La Torre, Giovanna Montana

Published in: Inflammation | Issue 1/2024

Login to get access

Abstract

The present study was conceived to examine the effects of inhibition of BMS-345541 mediated IKK kinase phosphorylation on the cellular defence system as well as on anti-inflammatory response and HSP90 activity. The analysis was conducted in A549 cell line, since such cells carry a homozygous Keap1 mutation (G333C) that alters its interaction with Nrf2. Recent data have highlighted that Keap1, HSP90 protein and IKK kinase interact reciprocally and particularly Keap1 protein is involved in HSP90 and anti-oxidative pathway regulation. The activities of COX2 and HO1 were investigated by real time and immunoblot analysis along with the synthesis and activity of inducible forms of heat shock protein HSP90. Pre-treatment with IKK kinase inhibitor proved to be a protective means to lower the activity of inflammatory cascade, so preventing the formation of excessive amounts of pro-inflammatory molecules. The inhibitor of IKK kinase BMS-345541 was added to cultured A549 cells before the Escherichia coli lipopolysaccharide (LPS) addition. The viability of the cells was determined after 1–24 h incubation with BMS-345541 at concentrations ranging from 1,25–5 µM. It was found that 1 µM concentration does not significantly affected cell viability (data not shown). As a result, the treatment with 1 μM of BMS-345541 induces the inhibition of IKK phosphorylation. In the A549 cells treated with BMS-345541 and LPS, COX2 activity is not induced: mRNA and protein levels have not increased, while there is an increase in the level of HSP90, HO1 proteins and mRNA. The results suggest that the IKK inhibition is effective in the reduction of the inflammatory response thanks to mechanisms involving both the heat shock cellular defense system and the antioxidative pathway.

Graphical Abstract

Literature
8.
go back to reference Ceribelli, M., P.N. Kelly, A.L. Shaffer, G.W. Wright, et al. 2014. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proceedings of the National Academy of Sciences of the United States of America 111(31): 11365–70. https://doi.org/10.1073/pnas.1411701111. Epub 2014 Jul 21. Ceribelli, M., P.N. Kelly, A.L. Shaffer, G.W. Wright, et al. 2014. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proceedings of the National Academy of Sciences of the United States of America 111(31): 11365–70. https://​doi.​org/​10.​1073/​pnas.​1411701111. Epub 2014 Jul 21.
12.
go back to reference Kim, J.E., D.J. You, C. Lee, C. Ahn, J.Y. Seong, and J.I. Hwang. 2010. Suppression of NF-κB signaling by KEAP1 regulation of IKKβ activity through autophagic degradation and inhibition of phosphorylation. Cellular Signalling 22: 1645–1654.CrossRefPubMed Kim, J.E., D.J. You, C. Lee, C. Ahn, J.Y. Seong, and J.I. Hwang. 2010. Suppression of NF-κB signaling by KEAP1 regulation of IKKβ activity through autophagic degradation and inhibition of phosphorylation. Cellular Signalling 22: 1645–1654.CrossRefPubMed
14.
go back to reference Ishii, T., K. Itoh, S. Takahashi, H. Sato, T. Yanagawa, Y. Katoh, S. Bannai, and M. Yamamoto, 2000. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. Journal of Biological Chemistry 275: 16023–16029. https://doi.org/10.1074/jbc.275.21.16023. Ishii, T., K. Itoh, S. Takahashi, H. Sato, T. Yanagawa, Y. Katoh, S. Bannai, and M. Yamamoto, 2000. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. Journal of Biological Chemistry 275: 16023–16029. https://​doi.​org/​10.​1074/​jbc.​275.​21.​16023.
18.
go back to reference Shibata, T., T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, et al. 2008. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National academy of Sciences of the United States of America 105: 13568–13573.CrossRefPubMedPubMedCentral Shibata, T., T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, et al. 2008. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proceedings of the National academy of Sciences of the United States of America 105: 13568–13573.CrossRefPubMedPubMedCentral
27.
go back to reference Broemer, M., D. Krappmann, and C. Scheidereit. 2004. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene 23: 5378–5386.CrossRefPubMed Broemer, M., D. Krappmann, and C. Scheidereit. 2004. Requirement of Hsp90 activity for IkappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. Oncogene 23: 5378–5386.CrossRefPubMed
28.
go back to reference Broemer, M., D. Krappmann, and C. Scheidereit. 2004. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 23: 5378–5386.CrossRefPubMed Broemer, M., D. Krappmann, and C. Scheidereit. 2004. Requirement of Hsp90 activity for IκB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-κB activation. Oncogene 23: 5378–5386.CrossRefPubMed
29.
33.
go back to reference Chen, G., P. Cao, and D.V. Goeddel. 2002. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Molecular Cell 9: 401–410.CrossRefPubMed Chen, G., P. Cao, and D.V. Goeddel. 2002. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Molecular Cell 9: 401–410.CrossRefPubMed
Metadata
Title
Effects of Inhibition of IKK Kinase Phosphorylation On the Cellular Defence System and HSP90 Activity
Authors
Miriam Giacomarra
Martina La Torre
Giovanna Montana
Publication date
29-08-2023
Publisher
Springer US
Published in
Inflammation / Issue 1/2024
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01894-3

Other articles of this Issue 1/2024

Inflammation 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine